Loading
Life sciences · Review
International Journal of Gynecology & Obstetrics · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Depressive disorders and clinically significant depressive symptoms are common in women with breast and gynecologic cancers, although prevalence estimates range from approximately 12% to more than 50% depending on instrument, threshold, timing, and setting. This narrative review, structured according to SANRA criteria, examines evidence on depression and oncologic outcomes in breast and gynecologic cancers and grades each claim by type and strength of evidence. Meta‐analyses of observational studies consistently associate depression with recurrence and with cancer‐specific and all‐cause mortality (pooled relative risks of approximately 1.2–1.3 in breast cancer), and with lower adherence to adjuvant endocrine therapy and radiotherapy. These are prognostic associations; residual confounding by stage, symptom burden, comorbidity, socioeconomic disadvantage, and access to care, and reverse causation, cannot be excluded. Neuroendocrine, inflammatory, and immune mechanisms are best characterized in ovarian cancer, largely in preclinical models and often in relation to chronic stress rather than clinical depression, and whether depression modifies the efficacy of immune checkpoint inhibitors in gynecologic cancers has not been studied. No adequately powered trial has tested whether treating depression improves cancer outcomes; available data come from broader psychosocial interventions and secondary analyses. We propose the Women's Biobehavioral Oncology Framework, an unvalidated conceptual model distinguishing depression as a prognostic marker, a possible causal contributor, and a treatment target, and a prioritized research agenda. Screening and treatment of depression are justified on clinical grounds; its use for risk stratification or treatment selection requires prospective validation.